Navigation Links
ReportsandReports: Biosimilars Series - Forecast Analysis Market Research Report
Date:2/2/2010

DALLAS, Texas, February 2 /PRNewswire/ -- ReportsandReports announce to have Biosimilars Series: Forecast Analysis (http://www.reportsandreports.com/market-reports/biosimilars-series-Forecast- Analysis/) Market Research Report in its store

The high cost and utilization of biologic drugs, coupled to the growing need to curb pharmaceutical expenditure, provides considerable momentum to the emerging biosimilars market. With a biosimilar approval pathway in place in Europe and Japan, and imminently in the US, Datamonitor expects payer pressure to drive biosimilar uptake, particularly in Germany, the US, and the UK.

    Scope

    - Molecule-specific forecasts for biosimilar epoetin alpha, filgrastim,
      interferon beta, interferon alpha, human growth hormone, and
      insulin-glargine.

    - Molecule-specific forecasts for France, Germany, Italy, Spain, the US,
      and Japan through 2019.

    - An overview of the emerging biosimilars market, including a regulatory
      update.

    - An outline of the key issues which will impact on biosimilars uptake
      going forward.

Highlights

As the first to introduce guidelines for biosimilar drug approval, Europe has emerged as the testing ground for biosimilar drugs, with biosimilars for three biologics having entered the market to date human growth hormone, epoetin alpha, and filgrastim.

The size of the US market, combined with the voracious generic erosion that characterize it, make it an attractive prospect for would-be biosimilars makers, and as such, it represents the real prize, contingent on the creation of a biosimilars approval pathway.

Although guidance for biosimilar approval was issued in Japan in 2009, this market is unlikely to experience significant biosimilar incursion through the forecast period, contributing at most 1% to total seven major market volume sales in 2019.

    Reasons to Purchase

    - Learn how biosimilar uptake for six biologic drugs is anticipated to
      change through 2019, in France, Germany, Italy, Spain, the UK, the US,
      and Japan.

    - Understand how the seven major markets compare in terms of speed and
      extent of biosimilars uptake.

    - Identify the key molecule and market specific drivers and resistors to
      biosimilar uptake.

Related Reports

HVAC in the U.S., 2nd Edition - Green and Global ( http://www.reportsandreports.com/market-reports/hvac-in-the-us-2nd-edition-%E 2%80%94-green-and-global/)

Global Biomaterial Market (2009-2014) ( http://www.reportsandreports.com/market-reports/global-biomaterial-market-200 9-2014/)

World Market for Biosimilars and the Potential for US Followon Biologics (http://www.reportsandreports.com/market-reports/world-market-for-biosimilars -and-the-potential-for-us-followon-bi/)

(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser's URL address field. Remove the space if one exists.)

    Contact:

    Ms. Sunita
    7557 Rambler road,
    Suite 727, Dallas, TX 75231
    Tel: +1-888-989-8004
    http://www.reportsandreports.com/


SOURCE MarketsandMarkets


'/>"/>
SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Globus Medical Raises $110 Million in Series E Financing Round
2. BioVascular Inc. Closes $10.87 Million Series C Financing
3. PG500 Series Presented at the AACR Annual Meeting in San Diego
4. Light Sciences Oncology Raises $40.1 Million in Series C Financing
5. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
6. ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing
7. Novare Announces Successful Series of Single Port Lap Band Procedures With RealHand(R) High Dexterity Instruments
8. Lutonix Inc. Announces $20 Million Series B Financing
9. Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series
10. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
11. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA ... drugs market is expected to grow at a CAGR of ... of 38.7% in the second half of the forecast period. The ... 2016 to 2027. The market is estimated at $1,058 million in ... ...
(Date:1/19/2017)... James Gilbart , ... 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... recently in a supplement to European Oncology & ... article by James Gilbart and ...
(Date:1/19/2017)... , Jan. 19, 2017   Science Exchange ... excited to announce that the first five replication ...  (RP:CB) have been published in eLife today. Despite ... represents the first practical evaluation of reproducibility rates ... reproducible studies. Unlike other assessments of reproducibility, the ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... January 21, 2017 , ... Salveo for life, a company that ... product to the United States as part of its presence to expand its market ... aims to reduce the productions of nasty toxins as a result of drinking alcohol, ...
(Date:1/21/2017)... ... January 21, 2017 , ... Phytocéane invites you to take ... rest of the world with ZANZIBAR SHOWER GEL. Inspired by the beauty of Zanzibar, ... Coconut Oil and moisturizing vegetal coral to create this gentle, crystal-clear shower gel to ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... new medical office in Petaluma, located at 167 Lynch Creek Way. The Petaluma ... SRO sports medicine and rehabilitation services and on-site x-ray services. Two ...
(Date:1/20/2017)... ... ... Launches New ADA Portable Motion Trek BP 300 Lift. Built for durability, this pool lift ... can be wheeled out of the way and stored when not in use. It is ... the feedback from customers into specific enhancements and created a new product that is built ...
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a ... percent pure essential oils, announced the company had a successful visit to the 2017 ... ECRM event gives companies that work in the nutritional, sports and health industries a ...
Breaking Medicine News(10 mins):